| Overview |
| bs-11975R |
| CACYBP/S100A6BP Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Mouse, Rat, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CACYBP/S100A6BP |
| 61-95/228 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cytoplasm, Nucleus |
| SIAH Interacting Protein; CACYBP; Calcyclin binding protein; GIG 5; GIG5; Growth inhibiting gene 5; Calcyclin-binding protein; Siah-interacting protein; Growth inhibiting gene 5 protein; hCacyBP; MGC87971; PNAS 107; PNAS107; RP1 102G20.6; S100A6 binding protein; S100A6BP; SIP. |
| CacyBP is a 228 amino acid protein encoded by the human gene CACYBP. CacyBP is primarily a nuclear protein that contains one CS domain and one SGS domain. CacyBP is believed to be involved in calcium-dependent ubiquitination and subsequent proteosomal degradation of target proteins. It most likely serves as a molecular bridge in ubiquitin E3 complexes. It also participates in the ubiquitin-mediated degradation of b-catenin. CacyBP is thought to be a potential inhibitor of cell growth and invasion in the gastric cancer cell through its effects on b-catenin protein expression and transcriptional activation of TCF/LEF. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz